Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of preoperative olaparib monotherapy and preoperative
olaparib plus pembrolizumab combination therapy in patients with untreated stage III, IV
high-grade serous or Grade 3 endometrioid ovarian cancer with Homologous Recombination
Deficiency (HRD) positivity.